Attachments:
FileDescriptionFile size
Download this file (HTL to present at Bloom Burton Conference  05.01.18.pdf)01-May-2017-Press-Release.pdfHamilton Thorne to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference21 kB

HAMILTON THORNE TO PRESENT AT THE 2018 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE 

BEVERLY, MA and TORONTO, Ontario – May 01, 2018 – Hamilton Thorne Ltd. (TSX-V: HTL), a leading world-wide provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne Ltd., will present at the 2018 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Hotel Toronto on Thursday May 3, 2018 at 11:00 a.m. Eastern Time.

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

 About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed and Embryotech Laboratories brands, through its growing sales force and distributors worldwide. Hamilton Thorne’s customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

 For more information, please contact:

David Wolf, President & CEO
Hamilton Thorne Ltd.    
978-921-2050 
ir [AT] hamiltonthorne [DOT] com
Michael Bruns, CFO
Hamilton Thorne Ltd.    
978-921-2050 
ir [AT] hamiltonthorne [DOT] com
Glen Akselrod
Bristol Investor Relations
905-326-1888
glen [AT] bristolir [DOT] com
 

Subscribe to Our Investor Email List